Cathepsin

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

Retrieved on: 
Tuesday, November 29, 2022

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
  • The grant will help fund a Phase 2 clinical study evaluating the companys targeted fluorescent imaging agent, VGT-309, for intraoperative imaging of tumors in patients undergoing lung cancer surgery.
  • We are grateful to the NCI for their support and to the team at the University of Pennsylvanias Perelman School of Medicine for conducting this Phase 2 study.
  • The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309

Retrieved on: 
Tuesday, October 4, 2022

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing.

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing.
  • The Series B funding brings the total raised by Vergent to date to $34 million.
  • Our previous clinical studies have validated the potential of VGT-309, and these additional funds will enable us to efficiently advance our current and future clinical trials in lung cancer.
  • Vergent intentionally designed VGT-309 to enable a complete solution for optimal tumor visualization during open, MIS, and robotic-assisted surgical procedures.

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Retrieved on: 
Tuesday, July 19, 2022

The FDA has cleared the Investigational New Drug (IND) application for a pharmacokinetic (PK) study in patients with impaired renal and hepatic function.

Key Points: 
  • The FDA has cleared the Investigational New Drug (IND) application for a pharmacokinetic (PK) study in patients with impaired renal and hepatic function.
  • SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro)inhibitor, STI-1558, in patients with impaired renal and hepatic function.
  • The Phase 1 study cleared by the FDA will examine the PK in patients with moderate renal and hepatic impairment.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.

Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster

Retrieved on: 
Friday, June 3, 2022

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro)inhibitor, STI-1558.

Key Points: 
  • SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro)inhibitor, STI-1558.
  • The world has been experiencing repeated waves of infection of SARS-CoV-2 and its continually emerging variants.
  • Oral antiviral drugs with broad-spectrum antiviral activities and limited potential for drug-drug interaction risks are still urgently needed.
  • ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.
    All other trademarks are the property of their respective owners.

Cathepsin K/S Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 8, 2019

The "Cathepsin K/S Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cathepsin K/S Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cathepsin K/S Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K/S Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Pipeline Products covered across the following Developmental Stages:
    Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

New Data From the MIV-711 Phase II Program Will be Presented at the ACR Annual Meeting on October 21

Retrieved on: 
Friday, October 19, 2018

There are currently no disease-modifying therapies approved for the treatment of the disease.

Key Points: 
  • There are currently no disease-modifying therapies approved for the treatment of the disease.
  • The ultimate goal for a treatment that inhibits structural damage or targets the underlying pathophysiology associated with osteoarthritis is to bring clinical benefit, such as reduction of pain.
  • It is however possible that structural endpoints could be accepted as valid outcome measures for accelerated approval in the US.
  • MIV-711 is a potent and selective inhibitor of cathepsin K, the principal protease involved in breaking down collagen in bone and cartilage.